Merriman Curhan Ford Maintains a 'Buy' on Cyclacel Pharmaceuticals (CYCC); Raises PT Range
CYCC Hot Sheet
Rating Summary:1 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 11 | New: 38
Merriman Curhan Ford maintains a 'Buy' on Cyclacel Pharmaceuticals (Nasdaq: CYCC), price target range $7-8.
Merriman analyst says, " Recall that Genzyme’s (Nasdaq: GENZ) Clolar was rejected for a similar indication at the hands of the FDA’s Oncologic Drugs Advisory Committee (ODAC) in September of this year, as was Vion’s (OTC: VION) laromustine. Also, Johnson and Johnson’s (NYSE: JNJ) Zarnestra showed no benefit (in fact, a slight decrease) in survival vs. best supportive care. Therefore, Cyclacel finds itself in an intriguing position as the putative leader in an exciting space with a Phase III ready asset that just might be the class leader. Given that the company’s valuation is barely $25M, we see continued upside potential in the stock from current levels."
To see all the upgrades/downgrades on shares of CYCC, visit our Analyst Ratings page.
Merriman analyst says, " Recall that Genzyme’s (Nasdaq: GENZ) Clolar was rejected for a similar indication at the hands of the FDA’s Oncologic Drugs Advisory Committee (ODAC) in September of this year, as was Vion’s (OTC: VION) laromustine. Also, Johnson and Johnson’s (NYSE: JNJ) Zarnestra showed no benefit (in fact, a slight decrease) in survival vs. best supportive care. Therefore, Cyclacel finds itself in an intriguing position as the putative leader in an exciting space with a Phase III ready asset that just might be the class leader. Given that the company’s valuation is barely $25M, we see continued upside potential in the stock from current levels."
To see all the upgrades/downgrades on shares of CYCC, visit our Analyst Ratings page.
You May Also Be Interested In
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Citi, Merriman Curhan FordSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
